

**Immunothrombosis and new-onset atrial fibrillation in the general population: the Rotterdam Study**

Martijn J. Tilly<sup>a</sup>, MD, Sven Geurts<sup>a</sup>, MD, Samantha J. Donkel<sup>b</sup>, MD, M. Arfan Ikram<sup>a</sup>, PhD,

Natasja M.S. de Groot<sup>c</sup>, PhD, Moniek P.M. de Maat<sup>b</sup>, PhD, \*Maryam Kavousi<sup>a</sup>, PhD

<sup>a</sup> Department of Epidemiology, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands

<sup>b</sup> Department of Hematology, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands

<sup>c</sup> Department of Cardiology, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands

**Corresponding author:** Maryam Kavousi

Erasmus MC, University Medical Center Rotterdam, office Na-2714

PO Box 2040, 3000 CA Rotterdam, The Netherlands

Telephone Number: +31 10 7043997

Email: m.kavousi@erasmusmc.nl

Journal: Clinical Research in Cardiology

## Online Resource 4. Association between markers of immunothrombosis and new-onset atrial fibrillation, stratified by sex

	Men		Women	
	Model 1 HR (95% CI)	Model 2 HR (95% CI)	Model 1 HR (95% CI)	Model 2 HR (95% CI)
Fibrinogen (g/L)	1.02 (0.92 – 1.13)	0.98 (0.88 – 1.09)	1.03 (0.92 – 1.16)	1.04 (0.93 – 1.17)
vWF:Ag (IU/mL)	1.04 (0.93 – 1.16)	1.01 (0.91 – 1.13)	1.06 (0.95 – 1.18)	1.05 (0.94 – 1.17)
ADAMTS13 (%)	1.00 (0.99 – 1.00)	1.00 (0.99 – 1.00)	1.01 (1.00 – 1.01)	1.01 (1.00 – 1.01)
vWF:Ag/ADAMTS13 ratio	1.06 (0.96 – 1.17)	1.04 (0.94 – 1.15)	0.97 (0.86 – 1.09)	0.96 (0.85 – 1.08)
MPO-DNA complex (mAU/mL)	0.98 (0.88 – 1.09)	0.98 (0.88 – 1.09)	1.04 (0.94 – 1.15)	1.04 (0.94 – 1.15)

Presented estimated are hazard ratio (95% confidence interval) per one standard deviation increase in each marker.

Model 1 is adjusted for age, and Rotterdam Study cohort. Model 2 is additionally adjusted for current smoking, hypertension, alcohol use, renal function, use of cardiac therapy, use of lipid-reducing agents, prevalent diabetes mellitus, prevalent heart failure, and prevalent coronary heart disease.

HR, Hazard Ratio; CI, Confidence Interval; vWF:Ag, von Willebrand Factor antigen; ADAMTS13, A Disintegrin And Metalloprotease with ThromboSpondin motif repeats 13.